Concord Wealth Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Concord Wealth Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1	Closed	-$31	–	831
2026 Q2	$31	Buy	+1	New	+$30	﹤0.01%	877
2026 Q1	–	Sell	-1	Closed	-$23	–	311
2025 Q4	$23	Hold	1	–	–	﹤0.01%	839
2025 Q3	$20	Hold	1	–	–	﹤0.01%	824
2025 Q2	$22	Hold	1	–	–	﹤0.01%	853
2025 Q1	$24	Hold	1	–	–	﹤0.01%	803
2024 Q4	$21	Hold	1	–	–	﹤0.01%	916
2024 Q3	$20	Hold	1	–	–	﹤0.01%	950
2024 Q2	$15	Hold	1	–	–	﹤0.01%	830
2024 Q1	$16	Buy	+1	New	+$15	﹤0.01%	846

Other funds holding CPRX

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Concord Wealth Partners's CPRX Position: Q3 2026 in Review

Concord Wealth Partners sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 1 share — an estimated $31 sold.

Concord Wealth Partners first reported a position in CPRX in Q1 2024 and held it in 9 quarters. The position peaked at $31 in Q2 2026. 1 fund tracked by Wall St. Rank holds CPRX as of Q3 2026.

Concord Wealth Partners reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Concord Wealth Partners sold 1 Catalyst Pharmaceutical share in Q3 2026, an estimated $31.
Concord Wealth Partners first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 9 quarters.
Concord Wealth Partners's Catalyst Pharmaceutical position peaked at $31 in Q2 2026.
1 fund tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Concord Wealth Partners's 13F filing for Q3 2026, filed 2 Nov 2026.